Salubrinal is a synthetic agent that inhibits the de-phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) and attenuates cellular stress to the endoplasmic reticulum. It has been also reported that it exerts beneficial effects on neuronal and skeletal diseases in various animal models. Recently, we have reported that salubrinal suppresses inflammatory responses in a mouse model of anti-collagen antibody-induced arthritis by inhibiting dual-specificity phosphatase 2 (Dusp2). Dusp2 is highly expressed in activated immune cells, and it dephosphorylates threonine and tyrosine residues on mitogen-activated protein kinases (MAPKs). A deletion of Dusp2 is shown to reduce inflammatory responses in the mouse model of rheumatoid arthritis. In this highlight, we describe salubrinal's action as a Dusp2 inhibitor and review salubrinal's beneficial effects on inflammatory responses.
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Beneficial effects of salubrinal in animal models
Salubrinal is a synthetic chemical agent which is known to specifically prevent the de-phosphorylation of eIF2α by inhibiting protein phosphatase 1 (PP1) [1] . It is also known as a suppressor of cellular stress to the endoplasmic reticulum, and salubrinal's therapeutic effects have been reported using animal models for various diseases. For instance, salubrinal is shown to attenuate β-amyloid-induced neuronal death as well as kainic acid-induced hippocampal cell death [2, 3] . Furthermore, it suppresses migratory behaviors of breast cancer cells through eIF2α-mediated downregulation of Rac1 GTPase [4] .
In skeletal tissues such as bones and joints, salubrinal is reported to promote osteoblastogenesis through upregulating activating transcription factor 4 (ATF4) [5] , and it suppresses osoteoclastogenesis through downregulating AP1 (e.g., c-Fos and JunB), and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) [6] . In chondrocyte cells activated by IL1β and TNFα, salubrinal is also reported to downregulate expression and activity of MMP13 through suppression of p38 and NFκB signaling [7] .
Salubrinal's suppression of inflammatory cytokines
We first examined whether salubrinal is able to suppress the action of inflammatory cytokines in activated immune cells. Primary macrophages and RAW264.7 cells were activated by lipopolysaccharide (LPS), while Jurkat T lymphocytes and HMC-1.1 mast cells were activated by phorbol myristate acetate (PMA) and ionomycin. Salubrinal
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reduced expression of inflammatory cytokines such as IL1β, Cox2, IL2, TNF, and IL13 in macrophages, T lymphocytes, and mast cells [8] .
Using genome-wide expression analysis, we next predicted a set of genes that potentially lead to salubrinal-driven suppression of inflammatory cytokines in activated immune cells. As two representative immune cells, we employed RAW264.7 cells as well as Jurkat cells. Principal component analysis (PCA) [9] of the gene expression values was performed to reduce the data's dimensions and identify principal axes that best represented the observed phenotype. The analysis revealed that along the first principal axis, the LPS-and PMA/ionomycin-stimulated cells were most positive, while salubrinal treated cells were between the unstimulated and stimulated cells. Additionally, dual-specificity phosphatase 2 (Dusp2) was well correlated with the first principal axis and was highly expressed in the LPS-stimulated RAW264.7 cells as well as PMA/ionomycin-stimulated Jurkat cells, while its expression was significantly suppressed by salubrinal [8] .
Dusp2 is a member of Dusp family that de-phosphorylates both phosphotyrosine and phosphoserine/phosphothreonine residues [10] . Many Dusps, including Dusp2, dephosphorylate threonine and tyrosine residues on mitogen-activated protein kinases (MAPKs) [11] , which play a critical role in immune responses. Dusp2 is an important regulator in inflammation, and Dusp2 knockout mice present significant reduction in inflammatory responses in the K/BxN model of rheumatoid arthritis [12] . In our study, Dusp2 was the only gene among the Dusp family of genes whose upregulation by both LPS and PMA/ionomycin was suppressed by salubrinal [8] . We also observed that a partial silencing of Dusp2 in RAW264.7 cells suppressed expression of inflammation genes such as IL1β and Cox2.
Salubrinal-driven suppression of inflammation in CAIA
In order to examine a novel therapeutic possibility of salubrinal for inflammatory arthritis, we employed a mouse model of anti-collagen antibody-induced arthritis (CAIA) [13] . Based on clinical scores as well as histological scores, salubrinal significantly decreased the inflammatory signs of CAIA mice in the fore and hind paws [8] .
Conclusion
We have demonstrated that in immune cells, salubrinal suppresses expression of inflammatory cytokines through the downregulation of Dusp2. Using a mouse model of inflammatory arthritis, we have also shown that salubrinal attenuates pathogenesis of inflammatory arthritis in the fore and hind paws. Collectively, the present study indicates that as an inhibitor of Dusp2, salubrinal may provide a novel therapeutic possibility for inflammatory arthritis such as rheumatoid arthritis.
